Preliminary Experience in Treating Lymphocytic Leukaemia with Antibody to Immunoglobulin Idiotypes on the Cell Surfaces

Overview

Journal Br J Cancer

Specialty Oncology

Date 1980 Oct 1

PMID 7192154

Citations 33

Authors

T J Hamblin

J Gordon

F K Stevenson

G T Stevenson

Affiliations

Soon will be listed here.

Abstract

Tumour-specific antiserum was raised in sheep against idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes from a patient with chronic lymphocytic leukaemia (prolymphocytic variant). The complement-activating IgG1 subclass of the anti-idiotype was prepared from the serum in monodisperse form for infusion. Two treatments of 480 and 1200 mg caused the white-cell count to fall by one-third and one-half respectively. However, there was a rapid resurgence, so that by 8 days after each treatment the counts were restored to approximately 85% of their former levels. No change was noted in the size of spleen or lymph nodes. Each treatment probably destroyed 4-8 X 10(11) cells, some 10% of the total tumour load. The antibody was rapidly consumed, and there was evidence of heavy utilization of complement.

Citing Articles

Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cells.

Kiefer M, Thurner L, Bock T, Cetin O, Kos I, Lesan V EJHaem. 2023; 4(1):125-134.

PMID: 36819155 PMC: 9928785. DOI: 10.1002/jha2.635.

The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.

Bewarder M, Kiefer M, Will H, Olesch K, Moelle C, Stilgenbauer S Hemasphere. 2021; 5(8):e620.

PMID: 34263144 PMC: 8274796. DOI: 10.1097/HS9.0000000000000620.

Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.

Bewarder M, Kiefer M, Moelle C, Goerens L, Stilgenbauer S, Christofyllakis K Front Oncol. 2020; 10:580364.

PMID: 33282736 PMC: 7689012. DOI: 10.3389/fonc.2020.580364.

Complement Activation in the Treatment of B-Cell Malignancies.

Zent C, Pinney J, Chu C, Elliott M Antibodies (Basel). 2020; 9(4).

PMID: 33271825 PMC: 7709106. DOI: 10.3390/antib9040068.

Therapeutic vaccines for aggressive B-cell lymphoma.

Xu-Monette Z, Young K Leuk Lymphoma. 2020; 61(13):3038-3051.

PMID: 32840404 PMC: 8344075. DOI: 10.1080/10428194.2020.1805113.

References

Porath J, Axen R, Ernback S . Chemical coupling of proteins to agarose. Nature. 1967; 215(5109):1491-2. DOI: 10.1038/2151491a0. View

Grey H, Rabellino E, PIROFSKY B . Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia. J Clin Invest. 1971; 50(11):2368-75. PMC: 292179. DOI: 10.1172/JCI106735. View

Fine D, Marney Jr S, Colley D, Sergent J, DES PREZ R . C3 shunt activation in human serum chelated with EGTA. J Immunol. 1972; 109(4):807-9. View

Scott J, McMillan R, MARINO J, Davidson J . Leukocyte labeling with 51 chromium. IV. The kinetics of chronic lymphocytic leukemic lymphocytes. Blood. 1973; 41(1):155-62. View

Manaster J, Fruhling J, Stryckmans P . Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a "readily accessible pool". Blood. 1973; 41(3):425-38. View

Proctor J, RUDENSTAM C, Alexander P . A factor preventing the development of lung metastases in rats with sarcomas. Nature. 1973; 242(5392):29-31. DOI: 10.1038/242029a0. View

Fakhri O, McLaughlin H, Hobbs J . 7S anti-tumour antibodies and activated Fc in macrophage tumour cell interaction. Eur J Cancer (1965). 1973; 9(1):19-23. DOI: 10.1016/0014-2964(73)90038-8. View

Kassel R, Old L, CARSWELL E, Fiore N, Hardy Jr W . Serum-mediated leukemia cell destruction in AKR mice. J Exp Med. 1973; 138(4):925-38. PMC: 2180560. DOI: 10.1084/jem.138.4.925. View

Themi H, TREPEL F, Schick P, KABOTH W, BEGEMANN H . Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients. Blood. 1973; 42(4):623-36. View

10.

GALTON D, Goldman J, Wiltshaw E, Catovsky D, Henry K, GOLDENBERG G . Prolymphocytic leukaemia. Br J Haematol. 1974; 27(1):7-23. DOI: 10.1111/j.1365-2141.1974.tb06769.x. View

11.

Eady R, Hough D, Kilshaw P, Stevenson G . Recovery of immunoglobulin removed from lymphocytic surfaces by proteolysis. Immunology. 1974; 26(3):549-61. PMC: 1423197. View

12.

LEECH J, Glick A, Waldron J, FLEXNER J, Horn R, Collins R . Malignant lymphomas of follicular center cell origin in man. I. Immunologic studies. J Natl Cancer Inst. 1975; 54(1):11-21. DOI: 10.1093/jnci/54.1.11. View

13.

Capra J, Kehoe J . Hypervariable regions, idiotypy, and the antibody-combining site. Adv Immunol. 1975; 20:1-40. DOI: 10.1016/s0065-2776(08)60205-9. View

14.

Stevenson G, Stevenson F . Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature. 1975; 254(5502):714-6. DOI: 10.1038/254714a0. View

15.

MacLennan I . Antibody in the induction and inhibition of lymphocyte cytotoxicity. Transplant Rev. 1972; 13:67-90. DOI: 10.1111/j.1600-065x.1972.tb00060.x. View

16.

Johansson B, Klein E, Haglund S . Correlation between the presence of surface localized immunoglobulin (Ig) and the histological type of human malignant lymphomas. Clin Immunol Immunopathol. 1976; 5(1):119-32. DOI: 10.1016/0090-1229(76)90155-0. View

17.

Grant C, Adams E, Miller H . Leukocyte-dependent antibody in sheep immunized with murine mastocytoma cells. Eur J Immunol. 1975; 5(5):324-30. DOI: 10.1002/eji.1830050507. View

18.

Hough D, Eady R, Hamblin T, Stevenson F, Stevenson G . Anti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes. J Exp Med. 1976; 144(4):960-9. PMC: 2190432. DOI: 10.1084/jem.144.4.960. View

19.

Stevenson G, ELLIOTT E, Stevenson F . Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed Proc. 1977; 36(9):2268-71. View

20.

Stevenson F, ELLIOTT E . Mediation of cytotoxic functions by classes and subclasses of sheep antibody reactive with cell surface immunoglobulin idiotypic and constant region determinants. Immunology. 1978; 34(2):353-8. PMC: 1457706. View